Physician profile
William Barba
NPI 1225053291
$2,357.77
in general payments reported to CMS, 2019-2025
17 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $57.74 · 2021: $337 · 2022: $328 · 2023: $682 · 2024: $525 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.73 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $549.31 | 2023-2025 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $317.21 | 2021-2024 | Prolaris |
| Janssen Biotech, INC. | $311.06 | 2019-2023 | Erleada |
| Astellas Pharma US INC | $283.63 | 2019-2023 | Xtandi, Myrbetriq |
| Pfizer INC. | $282.59 | 2019-2025 | |
| Progenics Pharmaceuticals, INC. | $139.20 | 2023-2025 | Pylarify |
| Abbvie INC. | $125.69 | 2021-2024 | Botox, Lupron Depot |
| Urovant Sciences INC | $69.01 | 2021-2022 | |
| Neotract INC. | $52.56 | 2019 | |
| Telix Pharmaceuticals | $48.34 | 2023 | Illuccix |
| Allergan, INC. | $46.23 | 2019 | |
| Tolmar, INC. | $38.51 | 2023 | |
| Merck Sharp & Dohme LLC | $31.98 | 2024 | Lynparza |
| Glaxosmithkline, LLC. | $21.76 | 2023 | Shingrix, Arexvy |
| Lumenis, INC | $15.93 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $12.81 | 2020 | |
| Boston Scientific Corporation | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Barba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.